# 1) Biological Warfare Defense Therapeutics

**R-2A activity** of project MT2 — Mitigate (Applied Research)  
**Program element:** 0602384BP — Chemical and Biological Defense Program  
**Component:** Defense-Wide · **Budget Activity:** 2  
**Vintage:** President's Budget PB2027  
**Canonical URL:** https://hitchintel.com/programs/0602384BP/MT2/a0  
**Parent:** https://hitchintel.com/programs/0602384BP/MT2

## Summary

This activity requests $21.7M in FY2027, 64% of project MT2, up 7.7% on FY2026. The R-2A exhibit describes it across FY2025–FY2027, including what the FY2027 money is planned to buy.

## What the FY2027 request buys

**FY2027 planned work.** - Discover and assess novel, broad-spectrum technologies to combat both known and unknown viral threats. - Conduct preliminary proof-of-concept effectiveness studies using proven pharmaceutical technologies that target multiple viral pathogens and/or clinical manifestations. - Explore and identify drug delivery systems that target specific tissues and improve the delivery of therapeutic candidates. - Create a therapeutic response matrix, a decision-making tool to guide the selection of the optimal treatment approach for both known and emerging threats. - Begin developing nanotechnologies for the non-specific removal of pathogens from a host organism. - Continue advancing the Biologics on Demand platform, enabling the on-site production of biologic therapies.

**FY2026 to FY2027 change.** Minor change due to routine program adjustments.

## Before the request year

**FY2026 plans — current year.** - Continue to evaluate new targets for development of broad-spectrum treatments. - Continue evaluation of broad spectrum platform therapeutic drug technologies. - Continue development and evaluation of novel broad-spectrum drug delivery capabilities and systems.

**FY2025 accomplishments.** - Initiated studies to identify host biological pathways that can be therapeutically targeted to reduce symptoms such as respiratory distress, cognitive impairment, and vascular dysfunction, supporting development of broad-spectrum, pathogen-independent treatments. - Initiated studies to discover therapeutics that minimize immune system damage as a result of pathogen infections. - Initiated development of efficacy and safety platforms for human-directed therapies to examine unintended consequences and allow for a reliable risk/benefit analysis. - Initiated development of novel therapeutic delivery systems to target infected tissues. - Continued development of AI-powered adaptive learning frameworks for creating broad-spectrum therapeutic solutions.

## Funding

| Fiscal Year | Estimate Type | Amount ($M) |
|---|---|---|
| FY2025 | Actual | 33.4 |
| FY2026 | Enacted | 20.1 |
| FY2027 | Request | 21.7 |

> Prior, current and budget year only — an R-2A activity carries no five-year plan. It sums exactly into its project in the request year and not necessarily in any other.

## Other activities in project MT2

- 3) Reactivators of Acetylcholinesterase as Therapeutics — FY2027 5.0
- 7) Equipment Decontamination — FY2027 2.5
- 8) Multifunctional Materials for Protection — FY2027 2.3
- 2) Enabling Science — FY2027 2.0
- 6) Enhanced Survivability Coatings — FY2027 0.5
- 4) Emerging and Pharmaceutical-based Agent Threats — FY2027 —
- 5) Chemically Reactive Ocular, Wound and Dermal Therapeutics — FY2027 —
- 9) Personnel Decontamination — FY2027 —
- 10) Discovery of Medical countermeasures Against New and Emerging threats - Enhanced Biological Defense — FY2027 —

## Source & machine access

- **Source:** FY2027 Office of the Secretary of Defense RDT&E Budget Justification, Exhibit R-2A, PE 0602384BP project MT2 (PB PB2027). Narrative is the government's own text.
- **No marks, no contractors at this grain** — congressional marks land on the program element and R-3 performers on the project.
- **MCP:** `mcp.hitchintel.com` — `budget_get_activity`.

*HitchAI is an independent intelligence service, not affiliated with the U.S. Department of Defense. Budget figures are requests/estimates, not obligations.*